Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Statins | Research article

Statin use and the risk of ovarian and endometrial cancers: a meta-analysis

Authors: Yizi Wang, Fang Ren, Zixuan Song, Peng Chen, Shuang Liu, Ling Ouyang

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

The relationship between statin use and the risk of ovarian or endometrial cancer remains controversial. Here, we investigated the relationship between statin use and the risk of ovarian and endometrial cancers.

Methods

We conducted a meta-analysis using articles retrieved from the PubMed, Embase, and Web of Science databases. All original comparative studies published in English that were related to statin use and the risk of ovarian or endometrial cancer were included.

Results

This meta-analysis included 19 studies enrolling 1,999,362 female subjects and 19,849 cancer cases (7,948 ovarian cancer cases and 11,901 endometrial cancer cases). The overall analysis indicated that statin use did not significantly reduce the risk of ovarian cancer [relative risk (RR) = 0.88, 95% confidence interval (CI) 0.76–1.03, p = 0.12] or the risk of endometrial cancer (RR = 0.88, 95% CI 0.78–1.00, p = 0.05.) Subgroup analyses based on study type, percentage of cancer cases, study location, and quality of studies also supported our conclusions. No association was found between long-term statin use (> 5 years) and the risk of ovarian cancer (RR = 0.73, 95% CI 0.51–1.04, p = 0.08) or endometrial cancer (RR = 0.79, 95% CI 0.58–1.08, p = 0.14).

Conclusions

Statin use did not lower the risk of ovarian cancer or endometrial cancer. The long-term use of statins (> 5 years) was not associated with a reduction in the risk of ovarian or endometrial cancer.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRef

Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013;131(3):772–9.CrossRef

Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–97.CrossRef

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11.CrossRef

Iannelli F, Lombardi R, Milone MR, Pucci B, De Rienzo S, Budillon A, Bruzzese F. Targeting mevalonate pathway in Cancer treatment: repurposing of statins. Recent Pat Anticancer Drug Discov. 2018;13(2):184–200.CrossRef

Kobayashi Y, Kashima H, Rahmanto YS, Banno K, Yu Y, Matoba Y, Watanabe K, Iijima M, Takeda T, Kunitomi H, et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget. 2017;8(42):72147–56.CrossRef

Zeybek B, Costantine M, Kilic GS, Borahay MA. Therapeutic roles of statins in gynecology and obstetrics: the current evidence. Reprod Sci. 2018;25(6):802–17.CrossRef

Schointuch MN, Gilliam TP, Stine JE, Han X, Zhou C, Gehrig PA, Kim K, Bae-Jump VL. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecol Oncol. 2014;134(2):346–55.CrossRef

Kato S, Liberona MF, Cerda-Infante J, Sanchez M, Henriquez JF, Bizama C, Bravo ML, Gonzalez P, Gejman R, Branes J, et al. Simvastatin interferes with cancer 'stem-cell' plasticity reducing metastasis in ovarian cancer. Endocr Relat Cancer. 2018. https://doi.org/10.1530/erc-18-0132.CrossRef

10.

Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P, Pisanti S, Santoro A, Caruso MG, Bifulco M. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme a reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. Endocr Relat Cancer. 2010;17(2):495–503.CrossRef

11.

Cuello FM, Kato CS, Diaz SD, Owen G. Effects of statins in cancer. Rev Med Chil. 2013;141(2):227–36.CrossRef

12.

Desai P, Wallace R, Anderson ML, Howard BV, Ray RM, Wu C, Safford M, Martin LW, Rohan T, Manson JE, et al. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative. Gynecol Oncol. 2018;148(3):540–6.CrossRef

13.

Akinwunmi B, Vitonis AF, Titus L, Terry KL, Cramer DW. Statin therapy and association with ovarian Cancer risk in the New England case control (NEC) study. Int J Cancer. 2018. https://doi.org/10.1002/ijc.31758.CrossRef

14.

Baandrup L, Dehlendorff C, Friis S, Olsen JH, Kjaer SK. Statin use and risk for ovarian cancer: a Danish nationwide case-control study. Br J Cancer. 2015;112(1):157–61.CrossRef

15.

Sperling CD, Verdoodt F, Friis S, Dehlendorff C, Kjaer SK. Statin use and risk of endometrial cancer: a nationwide registry-based case-control study. Biomed Res Int. 2017;96(2):144–9.

16.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.CrossRef

17.

Clark HD, Wells GA, Huet C, McAlister FA, Salmi LR, Fergusson D, Laupacis A. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20(5):448–52.CrossRef

18.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRef

19.

Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6(1):5–30.CrossRef

20.

Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154–76.CrossRef

21.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557–60.CrossRef

22.

Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics. 2000;1(3):247–62.CrossRef

23.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34.CrossRef

24.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.CrossRef

25.

Rennert G, Rennert HS, Pinchev M, Lavie O. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies. Gynecol Oncol. 2014;133(2):309–13.CrossRef

26.

Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007;18(2):213–9.CrossRef

27.

Yu O, Boudreau DM, Buist DS, Miglioretti DL. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control. 2009;20(5):609–16.CrossRef

28.

Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer. 2004;90(3):635–7.CrossRef

29.

Kabat GC, Kim MY, Chlebowski RT, Vitolins MZ, Wassertheil-Smoller S, Rohan TE. Serum lipids and risk of obesity-related cancers in postmenopausal women. Cancer Causes Control. 2018;29(1):13–24.CrossRef

30.

Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;17(1):27–36.CrossRef

31.

Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J, Puistola U, Laara E, et al. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study. Bjog. 2018;125(8):1001–8.CrossRef

32.

Fortuny J, Sima C, Bayuga S, Wilcox H, Pulick K, Faulkner S, Zauber AG, Olson SH. Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomark Prev. 2009;18(5):1448–56.CrossRef

33.

Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian simvastatin survival study (4S). Lancet. 2004;364(9436):771–7.CrossRef

34.

Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011;71(5):1763–71.CrossRef

35.

Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J. Incidence of cancer and statin usage--record linkage study. Int J Cancer. 2010;126(1):279–84.CrossRef

36.

Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol. 2013;130(3):615–9.CrossRef

37.

Leung HW, Chan AL, Lo D, Leung JH, Chen HL. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf. 2013;12(1):19–27.CrossRef

38.

Arima R, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Kangaskokko J, Laara E, Puistola U, Hinkula M. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes. Gynecol Oncol. 2017;146(3):636–41.CrossRef

39.

Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM. Air force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001;10(10):971–81.CrossRef

40.

Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160(15):2363–8.CrossRef

41.

Liu Y, Qin A, Li T, Qin X, Li S. Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. Gynecol Oncol. 2014;133(3):647–55.CrossRef

42.

Patel A, Huang KC, Janus ED, Gill T, Neal B, Suriyawongpaisal P, Wong E, Woodward M, Stolk RP. Is a single definition of the metabolic syndrome appropriate?--a comparative study of the USA and Asia. Atherosclerosis. 2006;184(1):225–32.CrossRef

43.

Lee JY, Jeon I, Kim JW, Song YS, Yoon JM, Park SM. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2013;23(3):402–12.CrossRef

44.

Shah MM, Erickson BK, Matin T, McGwin G Jr, Martin JY, Daily LB, Pasko D, Haygood CW, Fauci JM, Leath CA 3rd. Diabetes mellitus and ovarian cancer: more complex than just increasing risk. Gynecol Oncol. 2014;135(2):273–7.CrossRef

45.

Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015;129(7):872–80.CrossRef

46.

Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6–e15.CrossRef

47.

Wen Q, Zhao Z, Wen J, Zhou J, Wu J, Lei S, Miao Y. The association between metformin therapy and risk of gynecological cancer in patients: two meta-analyses. Eur J Obstet Gynecol Reprod Biol. 2019;237:33–41.CrossRef

48.

Cho MK. Use of combined Oral contraceptives in Perimenopausal women. Chonnam Med J. 2018;54(3):153–8.CrossRef

49.

Sjogren LL, Morch LS, Lokkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas. 2016;91:25–35.CrossRef

Title: Statin use and the risk of ovarian and endometrial cancers: a meta-analysis
Authors: Yizi Wang
Fang Ren
Zixuan Song
Peng Chen
Shuang Liu
Ling Ouyang
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Statins
Ovarian Cancer
Ovarian Cancer
Endometrial Cancer
Endometrial Cancer
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5954-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Diffuse cavernous hemangioma of the skull misdiagnosed as skull metastasis in breast cancer patient: one case report and literature review

Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer

MPPa-PDT suppresses breast tumor migration/invasion by inhibiting Akt-NF-κB-dependent MMP-9 expression via ROS

Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

Association between high-resolution MRI-detected extramural vascular invasion and tumour microcirculation estimated by dynamic contrast-enhanced MRI in rectal cancer: preliminary results

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer